A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma

source extracted confidence: high 2026-04-09
#antibodies-monoclonal #antineoplastic-agents #humans #iodine-radioisotopes #lymphoma-follicular

A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma

Rose et al., 2012 | Clin Lymphoma Myeloma Leuk | Meta Analysis

Citation

Rose Adam C, Shenoy Pareen J, ... Flowers Christopher R. A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2012-Dec;12(6):393-9. doi:10.1016/j.clml.2012.09.012

Abstract

BACKGROUND: Follicular lymphoma (FL) is characterized by multiple relapses and progressively shorter response durations with subsequent therapies. Despite the development of numerous treatment strategies to reduce the risk of progression, optimal therapeutic strategies for patients with FL remain undefined. Radioimmunotherapy (RIT) with an anti-CD20 antibody linked to iodine-131 or to yttrium-90 has emerged as well-tolerated treatment after induction. We conducted a systematic literature review and meta-analyses to quantify the benefits of consolidative RIT. METHODS: We searched the CENTRAL and MEDLINE libraries, and conference abstracts for reports on phase II/III clinical trials that assessed RIT consolidation for patients with untreated FL. Extracted data included pretreatment disease status, patient characteristics, treatment regimen, response rates, progression-free survival (PFS), and overall survival (OS). Pooled estimates of complete response (CR), overall response (OR), 2- and 5-year PFS and OS rates were computed by using random effects models. RESULTS: Eight studies (n = 783) were included in the meta-analyses. CR rates after RIT ranged from 69.0% to 96.5%, 2-year PFS ranged from 64.8% to 86.1%, and 5-year PFS ranged from 47.0% to 67.3%. The pooled estimates of the CR rate and OR rate were 82.7% (95% CI, 67.4%-91.7%) and 96.2% (95% CI, 90.4%-98.6%), respectively. The pooled estimates for 5-year PFS and OS were 57.6% (95% CI, 47.8%-66.9%) and 90.1% (95% CI, 83.9%-94.1%), respectively. CONCLUSIONS: We believe that these aggregated data can further the discussion on RIT as a consolidation therapy and inform decisions on future study designs Additional studies are needed to compare the benefits of RIT consolidation to maintenance therapy with rituximab.

Key Findings

Eight studies (n = 783) were included in the meta-analyses. CR rates after RIT ranged from 69.0% to 96.5%, 2-year PFS ranged from 64.8% to 86.1%, and 5-year PFS ranged from 47.0% to 67.3%. The pooled estimates of the CR rate and OR rate were 82.7% (95% CI, 67.4%-91.7%) and 96.2% (95% CI, 90.4%-98.6%), respectively. The pooled estimates for 5-year PFS and OS were 57.6% (95% CI, 47.8%-66.9%) and 90.1% (95% CI, 83.9%-94.1%), respectively.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population fl remain undefined
Sample Size 783
Age Range See abstract
Condition See abstract

MeSH Terms

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Humans
  • Iodine Radioisotopes
  • Lymphoma, Follicular
  • Radioimmunotherapy
  • Yttrium Radioisotopes

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review
  • Vertical: iodine

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09